Standardized SEC financial data for BOSTON SCIENTIFIC CORP — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0000885725 · NYSE · Surgical & Medical Instruments & Apparatus.
Ratios for fiscal year 2025, standardized from SEC filings.
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.91B | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B |
| Cost of revenue | $3.46B | $3.71B | $3.96B | $4.34B | $5.26B | $6.22B |
| Gross profit | $6.45B | $8.18B | $8.73B | $9.90B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.00B | $2.17B | $1.13B | $1.05B | $606.0M | $2.15B |
| Inventory | $1.35B | $1.61B | $1.87B | $2.48B | $2.81B | $2.94B |
| Total current assets | $6.69B | $6.32B | $5.76B | $6.51B |
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.51B | $1.87B | $1.53B | $2.50B | $3.44B | $4.53B |
| Capital expenditures | $376.0M | $554.0M | $588.0M | $711.0M | $790.0M | $876.0M |
| Free cash flow | $1.13B | $1.32B | $938.0M | $1.79B |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/BSX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/BSX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $11.49B |
| $13.85B |
| R&D expense | $1.14B | $1.20B | $1.32B | $1.41B | $1.61B | $2.05B |
| SG&A expense | $3.79B | $4.36B | $4.52B | $5.19B | $5.98B | $6.89B |
| Operating income | -$80.0M | $1.20B | $1.65B | $2.34B | $2.60B | $3.61B |
| EBITDA | $1.04B | $2.29B | $2.79B | $3.54B | $3.87B | $4.98B |
| Interest expense | $361.0M | $341.0M | $470.0M | $265.0M | $305.0M | $349.0M |
| Pretax income | -$79.0M | $1.08B | $1.14B | $1.99B | $2.28B | $3.38B |
| Income tax | $2.0M | $36.0M | $443.0M | $393.0M | $436.0M | $493.0M |
| Net income | -$115.0M | $985.0M | $642.0M | $1.57B | $1.85B | $2.90B |
| EPS (diluted) | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
Standardized from BOSTON SCIENTIFIC CORP's SEC filings — per-share figures split-adjusted. Full history via the API.
| $6.92B |
| $8.79B |
| Property, plant & equipment | $2.08B | $2.25B | $2.45B | $2.86B | $3.29B | $4.04B |
| Goodwill | $9.95B | $11.99B | $12.92B | $14.39B | $17.09B | $18.28B |
| Total assets | $30.78B | $32.23B | $32.47B | $35.14B | $39.40B | $43.67B |
| Total current liabilities | $3.68B | $4.27B | $3.80B | $4.93B | $6.40B | $5.44B |
| Long-term debt | $9.13B | $8.80B | $8.91B | $8.57B | $8.97B | $11.14B |
| Total debt | $9.13B | $8.80B | $8.91B | $8.57B | $8.97B | $11.14B |
| Total liabilities | $15.45B | $15.61B | $14.90B | $15.61B | $17.39B | $19.20B |
| Retained earnings | -$2.38B | -$1.39B | -$750.0M | $819.0M | $2.67B | $5.57B |
| Total equity | $15.33B | $16.62B | $17.57B | $19.53B | $22.00B | $24.47B |
| $2.65B |
| $3.66B |
| Investing cash flow | -$411.0M | -$1.60B | -$2.01B | -$2.57B | -$5.69B | -$2.64B |
| Financing cash flow | $293.0M | -$95.0M | -$548.0M | $5.0M | $1.81B | -$395.0M |
| Dividends paid | $28.0M | $55.0M | $55.0M | $28.0M | $0 | — |
| Share repurchases | $535.0M | $0 | $0 | — | — | — |